Senzime strengthens management - hires new CFO and Director of Business Development

Uppsala, June 7, 2016. Senzime AB (publ) has hired Jessica Roxhed as new CFO and Catrin Molund as new Director of Business development. Jessica joins with experience from various financial positions within Life Science and most recently the Church of Sweden, where she was controller. Catrin joins with a long term career in various management positions at Orexo AB, a publically traded specialty pharmaceutical company. Both will join from September 1.

"With the acquisition of Acacia, we took another important step towards building a global leader in patient monitoring. This increases the demands on us as an organization and I am very pleased that we managed to engage experienced professionals like Jessica and Catrin. Jessica with her financial and analytical skills plays an important role in a large and growing business. Catrin is a very driven and determined person we need as we approach the market with our products. I look forward to working with Jessica, Catrin and all employees to develop and position Senzime on the market, "says Lena Söderström, CEO of Senzime.

Translation

This is a translation of the Swedish original text.

For further information, please contact: Lena Söderström, CEO of Senzime AB
Tel: +46 708-16 39 12, email: lena.soderstrom@senzime.com

TO THE EDITORS
About Senzime
Senzime develops patient oriented systems enabling automated and continuous monitoring of vital substances such as glucose and lactate in blood and tissue. Based on Senzime's patented biosensor technology, the company offers complete patient monitoring systems for the health care market. Senzime's products consist of the CliniSenz Analyzer and OnZurf Probe that make it possible, among other things, to detect post-operative complications significantly earlier than by conventional methods, thus contributing to improved patient care and lower health care costs. In May 2016, Senzime broadened the scope and acquired Acacia Designs BV. The company's share is listed on Aktietorget, Stockholm. www.senzime.com

Acacia Designs

Acacia Designs is an international development company founded by leading clinicians and developers within the field of anesthesia. The company originates from research at Mayo Clinic, USA, the largest integrated non-commercial medical institution in the world and in 2015 ranked as the world's best hospital. Acacia has developed TetraGraph - a unique system for objective monitoring of patients undergoing anesthesia and the use of neuromuscular blocking agents (NMBAs). The system makes it possible to objectively determine the right dose of medication and when it is safe to wake the patient and allow for spontaneous breathing following surgery. Every year more than 20 million patients are affected by post-operative complications related to the use of NMBAs and premature extubation. The TetraGraph is intended to easily and precisely improve the monitoring of these patients to reduce complications and healthcare costs. Objective monitoring of patients receiving NMBAs is an established practice in several countries such as Scandinavia and France, and numbers of initiatives are underway to establish the method as Standard of Care. Acacia was founded in 2014 by Prof. Sorin J. Brull and Dr. David R. Hampton based on many years of research and development. www.acaciadesigns.eu